ARTHEx Biotech S.L. is a spin-off company of the University of Valencia that is developing antisense RNA treatments against genetic diseases. Our team has a strong background on drug discovery and microRNAs involvement in neuromuscular diseases. We are supported by world-renowned scientific and clinical advisors that will facilitate the successful development of our products.
“Antisense RNA treatment is a form of treatment for genetic disorders”.
Anti-microRNAs for the treatment of myotonic dystrophy
Our main objective is finding effective treatments to unmet medical needs. The first target of the company will be to investigate anti-microRNAs for the treatment of myotonic dystrophy Type 1 (DM1), which is an orphan disease affecting more than 900.000 people worldwide (estimated prevalence 1/8000). Our research reveled new therapeutic targets to treat the disease. The target and the mechanism of action of our molecules is new, and no other competitor has developed a similar approach.